Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 1c, beats revenue

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q2 EPS of ($1.09), $0.01 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $365.17 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79